Anti-CD9 monoclonal antibodies (MoAbs) are reported to activate human platelets through stimulation of the Fqll receptor. We show here that nonstimulatory F(ab'), fragments of the anti-CD9 MoAb 50H.19 induce dense-granule release and dose-dependent platelet aggregation when attached to polystyrene latex beads. Cross-linking F(ab'), fragments of MoAb 50H.19 by F(ab'), fragments of goat antimouse IgG does not result in platelet aggregation unless the second antibody is bound to latex beads, indicating that immobilization, and not cross-linking of the stimulus, is critical to the initiation of the CD9 signal. In contrast, F(ab'), fragments of the second antibody readily induce the aggrega-LTHOUGH THE PRECISE function of the human A cell surface glycoprotein CD9 is unknown, the striking ability of monoclonal antibodies (MoAbs) of the CD9 cluster to promote granule secretion and rapid platelet aggregati~n''~ suggests direct participation of CD9 in the initiation of signals leading to platelet activation. Of 107 antiplatelet MoAbs examined at the platelet workshop of the IV Leucocyte Typing Conference in Vienna, only 10 induced rapid platelet aggregation, of which nine were directed against CD9,8 suggesting that CD9 may be unique among platelet surface proteins in the potency with which it supports antibody-induced platelet activation. CD9 may therefore be a signal-initiating molecule. MoAbs to CD9 have been shown to stimulate intrinsic protein phosphorylation,7.9.10 ADP ribosylation,' phosphoinositide hydr~lysis,~ diacylglycerol f~r m a t i o n ,~ intracellular Caz+ flu^,^,",'^ and thromboxane s y n t h e s i~,~~~~'~ supporting the possibility that CD9 is involved in the induction of metabolic events under the regulation of phospholipase C. In most of these studies it was implicitly assumed that the antibody exerted its effect through stimulation of CD9. Recently, this assumption was challenged by the inability of soluble F(ab')z fragments of anti-CD9 MoAb to induce platelet activation and by the ability of MoAb directed to the FcyII receptor to prevent platelet aggregation and cytosolic calcium flux," suggesting that the signalling function may be mediated entirely through stimulation of the Fc receptor. We present here evidence that CD9 can initiate a platelet activation signal, but has a unique requirement that is not fulfilled by cross-linking. We show that nonstimulatory F(ab'), fragments of the anti-CD9 MoAb 50H.19 become potent platelet agonists when attached to polystyrene latex beads, and that the CD9 proximal signalling pathway is pharmacologically distinguishable from that induced by the intact MoAb.
A cell surface glycoprotein CD9 is unknown, the striking ability of monoclonal antibodies (MoAbs) of the CD9 cluster to promote granule secretion and rapid platelet aggregati~n''~ suggests direct participation of CD9 in the initiation of signals leading to platelet activation. Of 107 antiplatelet MoAbs examined at the platelet workshop of the IV Leucocyte Typing Conference in Vienna, only 10 induced rapid platelet aggregation, of which nine were directed against CD9,8 suggesting that CD9 may be unique among platelet surface proteins in the potency with which it supports antibody-induced platelet activation. CD9 may therefore be a signal-initiating molecule. MoAbs to CD9 have been shown to stimulate intrinsic protein phosphorylation,7.9.10 ADP ribosylation,' phosphoinositide hydr~lysis,~ diacylglycerol f~r m a t i o n ,~ intracellular Caz+ flu^,^,",'^ and thromboxane s y n t h e s i~,~~~~'~ supporting the possibility that CD9 is involved in the induction of metabolic events under the regulation of phospholipase C. In most of these studies it was implicitly assumed that the antibody exerted its effect through stimulation of CD9. Recently, this assumption was challenged by the inability of soluble F(ab')z fragments of anti-CD9 MoAb to induce platelet activation and by the ability of MoAb directed to the FcyII receptor to prevent platelet aggregation and cytosolic calcium flux," suggesting that the signalling function may be mediated entirely through stimulation of the Fc receptor. We present here evidence that CD9 can initiate a platelet activation signal, but has a unique requirement that is not fulfilled by cross-linking. We show that nonstimulatory F(ab'), fragments of the anti-CD9 MoAb 50H.19 become potent platelet agonists when attached to polystyrene latex beads, and that the CD9 proximal signalling pathway is pharmacologically distinguishable from that induced by the intact MoAb.
MATERIALS AND METHODS
Platelet preparation. Venous blood was collected from volunteers who denied taking medication for the 2 previous weeks. The blood was drawn into citrated vacutainer tubes and platelet-rich plasma (PRP) collected by centrifugation at 15% for 10 minutes at ambient temperature. Apyrase (0.1 U) (grade V; Sigma, St Louis, MO) and 10 ng/mL of prostacyclin (Sigma) were added per milliliter. Platelets were concentrated by centrifugation at 7OOg for 10 minutes and resuspended in 0.5 mL of Tyrode's-HEPES buffer containing 0.06 U/mL apyrase and 0.1% bovine serum albumin (BSA). Platelets were separated by passage over a 15-mL Sepharose 2B column (Pharmacia, Montreal, Quebec, Canada). The collected platelets were diluted to 5 mL and their concentration adjusted to 2 x lo8 platelets/mL. Platelet aggregation. Platelet aggregation was performed using column-washed platelets at 37°C in a Payton aggregometer (Payton, Scarborough, Ontario, Canada). All aggregation assays except those using thrombin were performed in the presence of 0.36 mg/mL of fibrinogen. The ADP scavenging system phosphocreatinelcreatine phosphokinase (CPICPK) was used at 5 mmol/L and 40 UImL of CP and CPK, respectively. The thromboxane receptor inhibitor BM13.177 (the kind gift of Dr Stegmeier, Boehringer-Mannheim, Germany) was used at 10 pmol/L and the cyclo-oxygenase inhibitor indomethacin at 20 p.mol/L. Changes in light transmission induced in 2 x 10' stirred platelets in a volume of 0.5 mL were used to quantitate aggregation. The reduction in light transmission due to the opacity of the latex beads was corrected by restoration of the baseline.
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RESULTS
To test whether the F(ah'), fragments of MoAb 50H.19 were contaminated with Fc fragments that might interact with the FcyII receptor, intact IgG and Fc-depleted F(ab'), fragments of MoAb 50H.19 were separated by sodium dodccyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted using horseradish peroxidase-conjugated Fc regionspecific IgG (Organon Teknika). The F(ab'), fragments were greater than 97% pure by the criteria of protcinstaining (Fig 1, lane 4) and reactivity with an Fc-specific Purity of F(ah'),fiapents.
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The aggregation Induced by 10 pglmL MoAb 50H.19 was lnhibtted by preincubation of the platelets wfth 10 pg/mL of MoAb IV.3. MoAb IV.3 was not stimulatory and did not prevent activation by 1 U/mL of thrombin. (Fig 1, lane 1) .
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The aggregation of gel-filtered human platelets induced by intact MoAb 50H.19 (Fig 2) was completely inhibited by prcincuhating the platelets with IO pg/mL of the anti-FcyII receptor MoAb IV.3 (Fig 2) , indicating that occupation of the Fc rcccptor is an obligatory requirement for generation of an anti-CD9 MoAb-induced activation signal as previously reported for the anti-CD9 MoAb SYB-I.''.'' MoAb IV.3 alone did not stimulate the platelets (Fig 2) , nor did it block the response to thrombin, suggcsting that its inhibitory activity was mediated through blockade of the Fc receptor (Fig 2) .
F(ab'), fiupents of MoAb 50H. 19 are nonstimirlatow irntil immobilized. F(ab'), fragments of MoAh 50H.19 did not stimulate platelet agregation (Fig 3) , as previously described for MoAb SYB-I."." However, presentation of the fragments on the surface of polystyrene latex beads resulted in rapid and complete platelet aggregation (Fig 3) . The activation could be competitively inhibited by soluble F(ab')2 fragments of MoAb 50H.19, indicating that it was mediated through stimulation of CD9 (Fig 3) . Latex beads exposed to BSA did not activate platelets, indicating that the beads themselves were incapable of inducing an activation signal (results not shown). Preincubation of the platelets with MoAb IV.3 had no effect on their activation by immobilized F(ab')2 fragments of MoAb 50H.19 (Fig 3) , precluding the possibility that the signal was elicited by contamination with uncleaved IgG. The number of beads added to the platelets and the degree of aggregation they induced showed a dose-response relationship (Fig 4) . Although we did not attempt to quantitate the number of active MoAb binding sites per bead, we estimated the amount of MoAb bound per bead by spectrophotometrically measuring the protein concentration of the antibody solution before and after adsorption to the beads. By this criterion, which would overestimate rather than underestimate the effective concentration of bound MoAb, the dose-response relationship was similar to that established for soluble intact anti-CD9 MoAb. from dense granules was evaluated (Table 1) . Soluble F(ab'), fragments of MoAb 50H.19 did not release 5HT over background (Table l) , as reported for F(ab')2 fragments of other agonistic anti-CD9 M o A~s . '~, '~ However, when the F(ab')2 fragments of MoAb 50H.19 were immobilized on polystyrene latex beads, 23% of total 5HT was released over background. In contrast, activation by intact MoAb 50H.19 resulted in 60% release. Because the height of the aggregation curves were similar, it suggests that 
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immobilized F(ab'), fragments provide a weaker stimulus for dense granule release, perhaps through selective activation of signals effecting degranulation. 5HT was not released by the nonstimulatory control MoAb 9H.1 ( Table 1) . The presence of either the ADP scavenger creatine phosphate/creatine phosphokinase (CP/CPK), the selective nonprostanoic thromboxane antagonist BM13.177," or the cyclo-oxygenase inhibitor indomethacin completely blocked 5HT secretion, suggesting that the release reaction, in common with aggregation, requires both secretion of ADP and stimulation of the thromboxane pathway (Table 1) .
Immobilization and not cross-linking of CD9 is required for
activation. Cross-linking nonstimulatory F(ab'), fragments of an anti-CD9 MoAb with an intact goat antimouse IgG as the second antibody is reported to cause platelet a~tivation,'~ suggesting that occupation of the FcyII receptor by the Fc region of the second antibody is the trigger. However, it cannot be ruled out that cross-linking of CD9 by the second antibody may also contribute to the response. To determine whether cross-linking CD9 alone is able to initiate a platelet-activating signal, F(ab'), fragments of MoAb 50H.19 were cross-linked by addition of F(ab'), fragments of a goat antimouse IgG antiserum. No aggregation was observed (Fig 5) , indicating that cross-linking of CD9 is insufficient to elicit a signal. Addition of F(ab'), fragments of the goat antimouse IgG antibody to platelets exposed to MoAb IV.3, however, promoted strong and rapid platelet aggregation (Fig 5) , showing that the F(ab'), fragments of the goat antimouse IgG could effectively cross-link murine MoAb, and suggesting that the FcyII receptor is qualitatively different from CD9 in its requirement for triggering. We reasoned that if immobilization of CD9 was required to initiate a signal, then attachment of the F(ab'), fragments of the second antibody to polystyrene latex beads would activate platelets in the presence of F(ab'), fragments of MoAb 50H.19. Attachment of the F(ab'), fragments of the goat antimouse IgG to latex beads did indeed result in a rapid and strong aggregation response (Fig 5) , supporting the postulate that immobilization is a critical requirement for initiation of the CD9 signal. To test whether platelets inherently respond to the immobilization of any potential antibody-binding site, MoAb against GPIb (AP-l), GPIb-GPIX (SZ-1), and HLA class I (9H.1) were attached to polystyrene beads either as intact MoAbs, or, in the case of SZ-1, as F(ab')2 fragments ( Table 2 ). None of the MoAbs or their fragments became stimulatory as a consequence of attachment to beads, indicating that immobilization of surface molecules per se does not cause signalling, and suggesting that the requirement for immobilization of the stimulus may be unique to CD9. Preincubation of platelets with cytochalasin B, an inhibitor of F-actin polymerization, completely prevented activation by immobilized F(ab'), fragments (Fig 3) , indicating that cytoskeletal assembly is a necessary requirement for CD9-induced aggregation.
Signalling by immobilized F(ab'), fragments of MoAb 50H. 19 but not by intact antibody has an absolute requirement for both ADP secretion and occupation of the thromboxane receptor. Stimulation of platelet aggregation by MoAb 50H.19 (Fig 6A) was only partially inhibitable by the ADP scavenger system CP/CPK (Fig 6A) or by the thromboxane receptor blocker BM13.177 (Fig 6A) , but was completely inhibited by their combination (Fig 6A) MoAb. In contrast, when platelets were activated by immobilized F(ab'), fragments of MoAb 50H.19, the aggregation was completely prevented by either the thromboxane receptor antagonist BM13.177 (Fig 6B) or by the ADP scavengers CP/CPK (Fig 6B) , implicating an absolute requirement for the activation of both pathways. The CD9 signal therefore appears to be qualitatively different from that induced by the intact MoAb and to specifically activate phospholipase A, independently and before the activation of phospholipase C.
DISCUSSION
We show here that platelets can be activated by immobilized F(ab'), fragments of anti-CD9 MoAb by a mechanism that is not inhibitable by Fc receptor blockade. This finding shows for the first time that CD9 can initiate a plateletactivating signal in the absence of Fc receptor stimulation, and implies that immobilization of CD9 by the activating stimulus may be a key requirement for initiation of an intracellullar signal. The immobilized F(ab'), MoAbinduced response appears to be specific for stimulation of CD4 because it is abrogated by soluble F(ab'), fragments of MoAb 50H.19. The CD9 proximal signal is characterized by its complete dependence on ADP secretion and a functional thromboxane pathway. Because the thromboxane receptor antagonist BM13.177 and the cylo-oxygenase inhibitor aspirin6 only slightly reduce platelet aggregation induced by intact MoAb 50H.19, it would appear that CD9-dependent signalling makes only a minor contribution to the MoAb 50H.19 activating signal, consistent with the observed aspirin-insensitivity of activation by the anti-CD9 MoAb ALB,.'*'3 One hundred and seventy MoAbs were tested in a workshop' of the IVth Leukocyte Typing Conference for their ability to promote platelet aggregation. Eighteen MoAbs induced some degree of platelet aggregation, of which six were directed against GPIIb/IIIa and 10 against CD9, suggesting that GPIIb/IIIa and CD9 may share a common property that allows for efficient stimulation of the Fc receptor. We have reported on the basis of chemical cross-linking studies that CD9 and GPIIb/ IIIa physically associate on the platelet surface under conditions of anti-CD9 MoAb stimulation: a possibility further supported by the ability of anti-GPIIb/IIIa MoAb to block platelet activation by anti-CD9 MoAb." GPIIb/ IIIa is known to cluster on occupation of the ligand-binding region, possibly through exposure of new sites for proteinprotein intera~ti0n.I~ It is probable therefore that CD9 and GPIIb/IIIa cocluster under appropriate stimulation, thereby achieving the local IgG concentration required to trigger the Fc receptor.
The need to immobilize either the primary or secondary antibody on a rigid support to achieve effective stimulation For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From through CD9 suggests to us the possibility that CD9 might be a component of a receptor system physiologically responsive to a mechanically rigid stimulus such as extracellular matrix. Our inability to produce even a small amount of platelet aggregation by cross-linking soluble F(ab')2 fragments of an anti-CD9 MoAb with F(ab')2 fragments of a goat antimouse IgG, although the latter effectively trigger platelet activation through cross-linking of the Fc receptor, suggests that CD9 and the Fc receptor are qualitatively different in their requirements for stimulation. MoAb directed to other platelet surface determinants immobilized on latex beads either as intact antibody or as F(ab'), fragments did not activate the platelet, indicating that immobilization of membrane proteins per se is not a trigger for generation of a platelet activating signal and emphasizing the specificity of this requirement for CD9. It is of interest that a similar requirement for immobilization rather than cross-linking has been shown for the activation of proliferation in T lymphocytes by MoAb directed against the T-cell receptor molecule CD3;' where the requirement may serve to physiologically restrict T-cell proliferation to T-cell-accessory cell interactiomw CD9-induced activation of the platelet, however, leads to the activation of metabolic pathways resulting in expression of an adherent rather than a proliferative phenotype. It is tempting to speculate that the physiologic consequence of the requirement for immobilization of CD9 to initiate a signal might be to restrict induction of adhesion to contact with the extracellular matrix. The notion that CD9 may function in the mechanoreception of an immobilized stimulus is appealing in the context of evidence for its association with the adhesion receptor GPIIb/IIIa6~1s and suggests a mechanism by which recognition of a component of the extracellular matrix by an integrin could be coupled through a responsive cytoskeleton to the initiation of intracellular signals effecting enhanced adhesiveness. It is of interest that platelet activation by fibrillar collagen, a major component of the subendothelial basement membrane, also proceeds via an aspirin-and cytochalasin B-sensitive involving the apparently independent activation of phospholipase A, and phospholipase C.21 Although the inability of F(ab')z fragments of anti-CD9 MoAb to inhibit the response of platelets to ~ollagen'~ would appear to rule out a role for CD9 in that response, such a role cannot be completely discounted because it has yet to be convincingly demonstrated that F(ab'), fragments of anti-CD9 MoAb are able to inhibit any aspect of platelet activation. The possibility that CD9 performs a signal-initiating function is compatible with the recent molecular cloning data indicating that CD9 is a multiply inserted membrane protein of novel structure containing four putative transmembrane domains.22 The extensive extracellular domain could function as a ligandbinding site. Although a ligand for CD9 has yet to be identified, our finding that CD9 requires immobilization to signal would predict that such a ligand would be located within the extracellular matrix. Alternatively, CD9 may be triggered indirectly through immobilization of the CD9-associative integrin through attachment to its ligand. Although the details of CD9-dependent signalling have yet to be established, our demonstration of an absolute requirement for a functional thromboxane pathway indicates that CD9 stimulates phospholipase C by the classical minoragonist route through prior activation of phospholipase A,, rather than through the thromboxane-independent component of Fc receptor signalling induced by the intact MOA^.'^,^^
In conclusion, the results presented here implicate CD9 as an independent initiator of platelet-activating signals. Further studies will be directed towards an understanding of the involvement of CD9 with members of the integrin family, the identification of possible ligands, and an understanding of the mechanisms of activation of phospholipases regulating metabolic pathways required for expression of the adherent phenotype. 
